This page reprints a manufacturer label. Everything below in quotation marks is copied from Bismusal Suspension, published by FDA and retrieved on 2026-09-16. Nothing has been added, reworded or left out of the sections shown. It is the manufacturer’s label, reproduced as published.
This page reprints the FDA label for Bismusal Suspension by Durvet, Inc, a salicylic acid product labelled for dogs and cats. The sections below are copied from that label without change, with the set id and the date it was retrieved from DailyMed. 6 other stored labels carry the same active ingredient and are listed at the end.
The label
Product: Bismusal Suspension. Manufacturer: Durvet, Inc. FDA Structured Product Label set id 36441ed4-7f17-45bb-94a9-5fc509266f69. Label effective 2022-11-14. Retrieved 2026-09-16 from the DailyMed animal label release, and readable on DailyMed.
Indications
A palatable oral suspension for use as an aid in controlling simple diarrhea in cattle, horses, dogs and cats.
Dosage and Administration
Administer orally. Dogs and Cats: 1 to 3 tablespoonfuls every 1-3 hours. Calves and Foals : 3 to 4 ounces every 2-3 hours. Horses and Cattle: 6 to 10 ounces every 2-3 hours. image of eye clock ACTIVE INGREDIENTS: Bismuth Subsalicylate......................1.75% w/w In a palatable aqueous suspension. Flavoring and coloring added. INACTIVE INGREDIENTS Water, Xanthan Gum, Sodium Saccharin, Methyl Salicylate, Magnesium Salicylate, Hydrochloric Acid, Methylparaben, Propylparaben, FD&C Red #40.
Warnings
If diarrhea persists after using this product for 2 days, consult a veterinarian.
Storage
Store at controlled room temperature between 15°-30°C (59°-86°F). Keep container tightly closed when not in use SHAKE WELL BEFORE USING. FOR ORAL USE ONLY. KEEP FROM FREEZING. Net Contents: One Gallon (3.785 L) Manufactured for: Durvet, Inc. Blue Springs, MO 64014 www.durvet.com image of made in usa flag image of LBDUMS120_r0415
Other labels for this ingredient
These labels are also stored for the same active ingredient. They are not identical to the one reprinted above, and each is listed by product and set id rather than merged with it.
- BISMUSOL, First Priority Incorporated. Set id 535cd0d9-cbd5-4d8f-8310-c2d672f18664.
- Bismusal Suspension, Durvet, Inc.. Set id f2e8b731-ab24-4c2c-a175-9664f54151f3.
- Bismuth, MWI/Vet One. Set id 0a03a7c2-212d-4fd3-a78a-616e59db3a41.
- Bismuth subsalicylate, Butler Animal health Supply, LLC dba Covetrus North America. Set id dc02ef3f-681e-4bc1-91ea-dbacd640f082.
- BISMU-KOTE, Vedco, Inc.. Set id 6f0731b9-3ac5-4aad-bb01-a0f6f4a9c18f.
- BISMUSOL In a Palatable Oral Suspension, Aspen Veterinary. Set id afe46400-352b-4ba9-838c-1748a0e82c21.
FDA adverse event reports
The FDA Center for Veterinary Medicine publishes the adverse event reports it receives through openFDA. The counts below are the reports naming salicylic acid as an active ingredient for each species this label names, as returned on 2026-09-16, coded by the VeDDRA reaction term the reporter chose. Reactions are counted per report, so one report can appear under several terms.
These are counts, not rates. Reporting is voluntary, the number of animals treated is not known, and a widely used product accumulates reports for that reason alone. A report records that an event followed a dose; it does not establish that the product caused it. The counts say nothing about how one product compares with another.
Dogs: 636 reports
| VeDDRA reaction term | Reports |
|---|---|
| Lack of efficacy - NOS | 189 |
| Loss of hearing | 64 |
| Deafness | 58 |
| Ear discharge | 50 |
| Ataxia | 46 |
| Behavioural disorder NOS | 44 |
| Lethargy (see also Central nervous system depression in 'Neurological') | 39 |
| Vomiting | 39 |
| Head tilt - ear disorder | 36 |
| Corneal ulcer | 34 |
| Anorexia | 26 |
| Ear pain | 26 |
| Head shake - ear disorder | 26 |
| Other abnormal test result NOS | 26 |
| Ear infection NOS | 23 |
Outcome as recorded by the reporter: Outcome Unknown 313; Recovered/Normal 142; Ongoing 141; Recovered with Sequela 19; Died 10; Euthanized 9.
Queries: reports, reactions, outcomes. Dataset: openFDA Animal and Veterinary Adverse Event Reports.
Cats: 85 reports
| VeDDRA reaction term | Reports |
|---|---|
| Ataxia | 29 |
| Horner's syndrome | 22 |
| Anorexia | 13 |
| Head tilt - ear disorder | 13 |
| Third eyelid protrusion | 13 |
| Vestibular disorder NOS | 13 |
| Not eating | 12 |
| Vomiting | 11 |
| Falling | 8 |
| Anisocoria | 7 |
| Decreased appetite | 7 |
| Hiding | 7 |
| Nystagmus | 7 |
| Weight loss | 7 |
| Horizontal nystagmus | 6 |
Outcome as recorded by the reporter: Outcome Unknown 43; Ongoing 19; Recovered/Normal 17; Euthanized 4; Recovered with Sequela 4.
Queries: reports, reactions, outcomes. Dataset: openFDA Animal and Veterinary Adverse Event Reports.
Sources
- Bismusal SuspensionFDA · retrieved 2026-09-16
“Administer orally. Dogs and Cats: 1 to 3 tablespoonfuls every 1-3 hours. Calves and Foals : 3 to 4 ounces every 2-3 hours. Horses and Cattle: 6 to 10 ounces every 2-3 hours. image of eye clock ACTIVE INGREDIENTS: Bismuth” (Dosage and Administration)
- openFDA Animal and Veterinary Adverse Event ReportsFDA · retrieved 2026-09-16
Related
From Glarda
The note drafted from the consult, with the reference you just read sitting beside it in the shape your record already expects.